Cell MedX EBIT

The latest EBIT for CMXC is $-700K as of August 2026. That compares with $-440K in the prior-year period — down 57.8% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Cell MedX's historical trend and sector peers before judging valuation or financial health.

Over the past year, CMXC's EBIT moved from $-440K to $-700K — a 57.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cell MedX's operating scale or balance-sheet position.

Against its sector companies, CMXC currently prints $-700K for EBIT, while the sector average sits near $2.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cell MedX's growth, margins, and balance sheet.

A EBIT figure of $-700K for CMXC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting CMXC's EBIT ($-700K), review year-over-year change from $-440K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.